Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12605264 | 0.91 | USP2 (0.43) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL8242595 | 0.86 | USP2 (0.61) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL2225547 | 0.85 | HSD11B1 (0.49) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL11344621 | 0.84 | USP2 (0.45) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL12644325 | 0.83 | USP2 (0.50) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL46682 | 0.83 | USP2 (0.50) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL7605519 | 0.83 | TLR8 (0.46) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL22123127 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL20873847 | 0.83 | USP2 (0.53) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL23251655 | 0.83 | USP2 (0.46) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694874-A2 | GPX4 INHIBITORS AND SENOLYTIC COMPOUNDS AND USES THEREOF | Rubedo Life Sciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260007689-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | RUBEDO LIFE SCIENCES INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12485132-B2 | GPX4 inhibitors and senolytic compounds and uses thereof | Rubedo Life Sciences, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250319109-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | RUBEDO LIFE SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20240408124-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | Rubedo Life Sciences, Inc. | 2024-12-12 | — | — | US | disclosed |
| WO-2024249613-A2 | GPX4 INHIBITORS AND SENOLYTIC COMPOUNDS AND USES THEREOF | Rubedo Life Sciences, Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-11 | — | — | US | disclosed |
| EP-2857401-B1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | MEIJI SEIKA PHARMA CO LTD (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-20180258089-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-10023573-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-07-17 | — | — | US | disclosed |
| US-20170233393-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-9708320-B2 | β-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-9181250-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | USP2 1652/4885SMN1; SMN2 702/4885CHRM2 634/4885 |
| US-20260007689-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | GPX4, GPX1, PRDX4 | USP2 505/4885SMN1; SMN2 1652/4885CHRM2 4143/4885 |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, MRPL21, FNTB | USP2 2510/4885SMN1; SMN2 2245/4885CHRM2 1617/4885 |
| US-20250319109-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | GPX4, GPX1, PRDX3 | USP2 518/4885SMN1; SMN2 2968/4885CHRM2 4761/4885 |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, FN1, FNTB | USP2 2674/4885SMN1; SMN2 2493/4885CHRM2 1277/4885 |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | USP2 1652/4885SMN1; SMN2 702/4885CHRM2 634/4885 |
| US-20180258089-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | USP2 1652/4885SMN1; SMN2 702/4885CHRM2 634/4885 |
| US-10023573-B2 | Beta-lactamase inhibitor and process for preparing the same | FN1, FNTB, CPN1 | USP2 669/4885SMN1; SMN2 1523/4885CHRM2 1270/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | USP2 1652/4885SMN1; SMN2 702/4885CHRM2 634/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | USP2 1652/4885SMN1; SMN2 702/4885CHRM2 634/4885 |
| US-20240408124-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | GPX4, GPX1, PRDX3 | USP2 518/4885SMN1; SMN2 2968/4885CHRM2 4761/4885 |
| US-12485132-B2 | GPX4 inhibitors and senolytic compounds and uses thereof | GPX4, GPX1, PRDX3 | USP2 518/4885SMN1; SMN2 2968/4885CHRM2 4761/4885 |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | USP2 1652/4885SMN1; SMN2 702/4885CHRM2 634/4885 |
| US-20170233393-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | FN1, FNTB, CPN1 | USP2 669/4885SMN1; SMN2 1523/4885CHRM2 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.